Back to Quality Research
STESTERIS plc
Health Care · Health Care Equipment · Large
$232.15−0.03%
As of 23 Oct 2026Mkt cap $22.5B
Stage 13
BUY
Fundamentals
56.5/75
Technical
12.3/15
Independent
68.8/90
GCAE viewstrong Fundamental /75 and actionable Technical v2 timing align · Rotation is a supportive tailwind but contributes no score points
Price
- 1M
- +11.2%
- 3M
- +6.3%
- 6M
- +4.7%
- 1Y
- −4.2%
Financials & valuation
Cached filing evidence · as of 2026-10-02
Valuation
- P/E
- 28.4xHist median 38.5x
- Forward P/E
- —No validated forward-estimate source
- Price / FCF
- 24.8x
- FCF yield
- 4.0%
Quality
- ROIC
- 9.4%
- Operating margin
- 16.3%
- FCF margin
- 16.4%
- Current ratio
- 2.1x
Growth
- Revenue growth
- +8.7%Latest FY YoY
- Revenue CAGR
- +8.9%
- EPS CAGR
- +33.7%
- FCF CAGR
- +25.1%
Capital
- Share-count trend
- −0.4%3Y annualised
- Net debt
- $1.6B1.2x OCF
Annual trend
- CAGR 2022–2026
- +8.9%
- Latest · 2026
- $6B
- YoY
- +8.7%
GCAE Research
- Quality Research
- MIXED
- Acceleration Radar
- NOT FLAGGED
- THE ONE
- NOT FLAGGED
- Final / Opportunity
- UNRESEARCHED · NEW RESEARCH
Key takeaway
Fresh 24 October review found no material company-specific evidence sufficient to change the approved qualitative verdict; the stated watch items remain unresolved.
Unresolved question
No reliable unresolved question is available from the current committed evidence.
Watch next
- RAPICIDE remediation and any expansion of affected products
- Healthcare/AST organic service and consumable growth
- chemistry project milestones and free-cash-flow conversion
More details & evidence
Production decision
- Stage 13
- BUY
- Technical state
- confirmed-recovery
- Rotation
- tailwind
- Evidence
- fresh
Presentation freshness
- Stage 11 market
- 2026-10-23 · Massive
- Financial cache
- 2026-10-02
- Quality Research
- CURRENT
- THE ONE
- NOT FLAGGED
Authority
- Company page
- Presentation only
- Scores
- Frozen GCAE production outputs
- Research
- Research-only lanes; no score override
- Private portfolio
- Not loaded